Mapatumumab

Mapatumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TRAIL-receptor (death receptor 4)
Clinical data
ATC code	none;
Identifiers
CAS Number	658052-09-6 ;
ChemSpider	none;
UNII	WZ1025JPGR;
Chemical and physical data
Formula	C6748H10408N1800O2092S52
Molar mass	151891.12 g·mol−1
	(what is this?) (verify)

Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.^[1] It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types.^[2]

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Mapatumumab, American Medical Association.
^ Moretto P, Hotte SJ (March 2009). "Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1". Expert Opinion on Investigational Drugs. 18 (3): 311–25. doi:10.1517/13543780902752463. PMID 19243282. S2CID 71176481.

[1] Statement On A Nonproprietary Name Adopted By The Usan Council - Mapatumumab, American Medical Association.

[2] Moretto P, Hotte SJ (March 2009). "Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1". Expert Opinion on Investigational Drugs. 18 (3): 311–25. doi:10.1517/13543780902752463. PMID 19243282. S2CID 71176481.

[1]

[2]